Dongcheng Pharmaceutical’s subsidiary’s new prostate cancer drug approved for clinical trials
October 5, 2025
Source: https://www.stcn.com/article/detail/3353547.html
142
Dongcheng Pharmaceutical recently announced that its controlling subsidiary, Lannacheng, has received approval from the National Medical Products Administration (NMPA) for the clinical trial of 225Ac-LNC1011 injection, authorizing it to conduct clinical trials for prostate cancer. This drug, an alpha-particle radioactive in vivo therapeutic targeting prostate-specific membrane antigen (PSMA), is intended for the treatment of patients with advanced prostate cancer who are PSMA-positive. Currently, no similar product is marketed outside of China , and no sales data is available. The project has invested approximately 14.53 million yuan in R&D.
In completed animal and human trials, 225Ac-LNC1011 injection has demonstrated therapeutic potential for prostate cancer. However, the drug development cycle, clinical trial approval, and production are long and involve many steps. Investors need to be aware of the risk of drug development failure.
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
